-
1
-
-
82155177961
-
Public Health Service Act Sec. 262. Regulation of biological products
-
Public Health Service Act Sec. 262. Regulation of biological products. , http://www.fda.gov/RegulatoryInformation/Legislation/ucm149278.htm
-
-
-
-
2
-
-
34447503942
-
The FDA's assessment of follow-on protein products: a historical perspective
-
10.1038/nrd2307, 17633790
-
Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, Hixon D, Joneckis C, Kozlowski S, Rosenberg A, Schrager L, Shacter E, Temple R, Webber K, Winkle H. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007, 6:437-442. 10.1038/nrd2307, 17633790.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 437-442
-
-
Woodcock, J.1
Griffin, J.2
Behrman, R.3
Cherney, B.4
Crescenzi, T.5
Fraser, B.6
Hixon, D.7
Joneckis, C.8
Kozlowski, S.9
Rosenberg, A.10
Schrager, L.11
Shacter, E.12
Temple, R.13
Webber, K.14
Winkle, H.15
-
3
-
-
82155174451
-
Yisaipu
-
Yisaipu. , http://www.cpgj-pharm.com/en/product_patient.asp?proid=22&action=intro
-
-
-
-
4
-
-
80055096139
-
Etanar therapy in real-life patients with rheumatoid arthritis [abstract]
-
Rondon F, Bautista A, Salazar JC, Casas N, Santos P, Vargas F, Marquez J. Etanar therapy in real-life patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2010, 62(Suppl 10):1811.
-
(2010)
Arthritis Rheum
, vol.62
, Issue.SUPPL. 10
, pp. 1811
-
-
Rondon, F.1
Bautista, A.2
Salazar, J.C.3
Casas, N.4
Santos, P.5
Vargas, F.6
Marquez, J.7
-
5
-
-
82155187689
-
Pipeline products
-
Pipeline products. , http://www.protalix.com/pipeline_products.html
-
-
-
-
6
-
-
82155174447
-
Biosimilar TuNEX® completes Phase I/II clinical trial in Taiwan, Phase I in Korea
-
Biosimilar TuNEX® completes Phase I/II clinical trial in Taiwan, Phase I in Korea. , http://www.mycenax.com.tw/webe/html/02news/news_show.aspx?page=1
-
-
-
-
7
-
-
82155187690
-
Avesthagen gets patent for Enbrel biosimilar
-
Singh K. Avesthagen gets patent for Enbrel biosimilar. Economic Times 2010,
-
(2010)
Economic Times
-
-
Singh, K.1
-
8
-
-
82155169551
-
Korea's Celltrion and Aprogen in race to sell biosimilars in Japan
-
Korea's Celltrion and Aprogen in race to sell biosimilars in Japan. , http://sis.windhover.com/buy/abstract.php?id=28101102003
-
-
-
-
9
-
-
82155169550
-
LG Life Sciences' Pipeline Overview
-
LG Life Sciences' Pipeline Overview. , http://thinklgls.com/rnd/pipeline
-
-
-
-
10
-
-
82155174450
-
Dr. Reddy's Marketed Pharmaceutical Products
-
Dr. Reddy's Marketed Pharmaceutical Products. , http://www.drreddys.com/products/bio_mproducts.html#
-
-
-
-
11
-
-
82155187691
-
TL011 in severe, active rheumatoid arthritis patients
-
TL011 in severe, active rheumatoid arthritis patients. , http://clinicaltrials.gov/ct2/show/NCT01123070
-
-
-
-
12
-
-
82155169552
-
GP2013 in the treatment of RA patients refractory to or intolerant of standard therapy
-
GP2013 in the treatment of RA patients refractory to or intolerant of standard therapy. , http://www.clinicaltrials.gov/ct2/show/NCT01274182
-
-
-
-
13
-
-
82155177960
-
View Opportunities
-
View Opportunities. , http://www.sourcegenerics.com/viewAllListing.asp
-
-
-
-
14
-
-
0031841745
-
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)
-
Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998, 50:1266-1272.
-
(1998)
Neurology
, vol.50
, pp. 1266-1272
-
-
Rudick, R.A.1
Simonian, N.A.2
Alam, J.A.3
Campion, M.4
Scaramucci, J.O.5
Jones, W.6
Coats, M.E.7
Goodkin, D.E.8
Weinstock-Guttman, B.9
Herndon, R.M.10
Mass, M.K.11
Richert, J.R.12
Salazar, A.M.13
Munschauer, F.E.14
Cookfair, D.L.15
Simon, J.H.16
Jacobs, L.D.17
-
15
-
-
0037075272
-
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
-
10.1056/NEJMoa011931, 11844847
-
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475. 10.1056/NEJMoa011931, 11844847.
-
(2002)
N Engl J Med
, vol.346
, pp. 469-475
-
-
Casadevall, N.1
Nataf, J.2
Viron, B.3
Kolta, A.4
Kiladjian, J.J.5
Martin-Dupont, P.6
Michaud, P.7
Papo, T.8
Ugo, V.9
Teyssandier, I.10
Varet, B.11
Mayeux, P.12
-
16
-
-
33745096842
-
Eprex-associated pure red cell aplasia and leachates
-
10.1038/nbt0606-613, 16763579
-
Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006, 24:613-614. 10.1038/nbt0606-613, 16763579.
-
(2006)
Nat Biotechnol
, vol.24
, pp. 613-614
-
-
Schellekens, H.1
Jiskoot, W.2
-
17
-
-
4644351840
-
Pure red-cell aplasia and epoetin therapy
-
10.1056/NEJMoa040528, 15459301
-
Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004, 351:1403-1408. 10.1056/NEJMoa040528, 15459301.
-
(2004)
N Engl J Med
, vol.351
, pp. 1403-1408
-
-
Bennett, C.L.1
Luminari, S.2
Nissenson, A.R.3
Tallman, M.S.4
Klinge, S.A.5
McWilliams, N.6
McKoy, J.M.7
Kim, B.8
Lyons, E.A.9
Trifilio, S.M.10
Raisch, D.W.11
Evens, A.M.12
Kuzel, T.M.13
Schumock, G.T.14
Belknap, S.M.15
Locatelli, F.16
Rossert, J.17
Casadevall, N.18
-
18
-
-
82155174449
-
Federal Food, Drug, and Cosmetic Act (FD&C Act) SEC. 505. [21 USC §355] New Drugs
-
Federal Food, Drug, and Cosmetic Act (FD&C Act) SEC. 505. [21 USC §355] New Drugs. , http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm108125.htm
-
-
-
-
19
-
-
33644952525
-
Guideline on similar biological medicinal products
-
London: European Medicines Agency, Committee for Medicinal Products for Human Use
-
Committee for Medicinal Products for Human Use Guideline on similar biological medicinal products. 2005, London: European Medicines Agency, Committee for Medicinal Products for Human Use.
-
(2005)
-
-
-
20
-
-
42049123626
-
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues
-
London: European Medicines Agency, Committee for Medicinal Products for Human Use
-
Committee for Medicinal Products for Human Use Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006, London: European Medicines Agency, Committee for Medicinal Products for Human Use.
-
(2006)
-
-
-
21
-
-
82155187686
-
Work plan for the biosimilar medicinal products working party (BMWP) 2011
-
London: European Medicines Agency, European Medicines Agency
-
European Medicines Agency Work plan for the biosimilar medicinal products working party (BMWP) 2011. 2010, London: European Medicines Agency, European Medicines Agency.
-
(2010)
-
-
-
22
-
-
82155187688
-
H. R. 3590--686. Patient Protection and Affordable Care Act. Title VII-- Improving Access to Innovative Medical Therapies. Subtitle A--Biologics Price Competition and Innovation. Sec. 7002. Approval Pathway for Biosimilar Biological Products
-
H. R. 3590--686. Patient Protection and Affordable Care Act. Title VII-- Improving Access to Innovative Medical Therapies. Subtitle A--Biologics Price Competition and Innovation. Sec. 7002. Approval Pathway for Biosimilar Biological Products. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf
-
-
-
-
23
-
-
79959636415
-
Implementation of the Biologics Price Competition and Innovation Act of 2009
-
Implementation of the Biologics Price Competition and Innovation Act of 2009. , http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm215089.htm
-
-
-
|